Good Fellow Healthcare Holdings Limited Overview
Good Fellow Healthcare is a micro-cap, Hong Kong-headquartered holding company listed on GEM. It is in the middle of a forced transition from owner-operator of PRC general hospitals to an asset-light healthcare-services and hospital-management platform.
Its only physical hospital, in Beijing (now named Beijing Huicheng Hospital, formerly Beijing Zijing), has been suspended since 12 December 2024 and produced no revenue in FY2026. Revenue of HK$20.06m in FY2026 came almost entirely from a five-year operating-management agreement with the Yueerwan (Qingdao) Internet Hospital. That agreement carries a contractual minimum fee of HK$1.75m per month.
Management's stated ambition is an "integrated healthcare-services platform" anchored on specialty hospitals. Current projects include:
-
a licensed but unbuilt Grade III specialty hospital in Hainan's Boao Lecheng Pilot Zone;
-
a proposed RMB5.74m purchase of a look-through 40.8% interest in a 30-year-old Xiamen secondary hospital.
The group is founder-controlled, has very low liquidity and depends on frequent equity issuance.
Company's own description
In its FY2026 annual report, the Company describes itself as an investment holding company whose subsidiaries are principally engaged in providing general hospital services in the PRC [AR26, Report of the Directors].
The FY2026 outlook restates the group objective. The aim is an integrated healthcare-services platform in the PRC, anchored on specialty hospital services and complemented by hospital management and digital-healthcare cooperation [AR26, MD&A].
Market data vendors describe the historic service scope as medical and surgical wards, cosmetic surgery, dermatology, and medical check-up and examination services [AGG, Morningstar]. A company profile on moomoo describes a "Jinwei Medical Model" of medical investment, M&A, management consulting, special planning, training and entrusted hospital management [AGG, moomoo company page].
Independent characterisation
In economic substance, Good Fellow is no longer a hospital operator in FY2026. It is a management-services contractor with an option on future hospital assets.
Revenue model.
FY2024: 100% point-in-time patient revenue from hospital services, totalling HK$38.962m [AR25-RA, Note 5].
FY2025: HK$10.945m point-in-time hospital revenue plus HK$5.175m recognised over time. The over-time amount is consistent with management-service fees under the October 2024 Yueerwan agreement [AR25-RA, Note 5; AR26 revenue recognition policy].
FY2026: No hospital segment revenue [AR26, Chairman's Statement]. Effectively all HK$20.060m was hospital-management services revenue, recognised straight-line (derived).
Revenue mix by type (FY2026, derived). Services 100%, products 0%, subscription/licensing 0%. The management fee is contractually a minimum fixed monthly fee, so it behaves like a recurring service retainer.
Value-chain position. The group sits at the provider/operator layer of PRC healthcare delivery:
-
historically as a private hospital owner (Putian, Jiaxing, Beijing);
-
currently as an outsourced operating partner to an internet hospital licensed to a third party (Yueerwan Qingdao).
Customer types.
-
Historically: retail patients, self-pay and insured.
-
Currently: a single B2B counterparty (Yueerwan Qingdao/Xiamen Yueerwan).
The FY2026 annual report states that no individual customer contributed over 5% of revenue [AR26]. That is difficult to reconcile with a single management contract that delivered principal revenue. The likely explanation is that "customers" is defined at the patient level, or that the statement carried over boilerplate. This is a disclosure inconsistency investors should query.
End-markets.
-
Mainland China private hospital services.
-
Internet hospital and telemedicine operations.
-
Prospective medical tourism and specialty care in the Hainan Free Trade Port (Boao Lecheng).
Strategy
Stated strategy (themes from AR26)
Integrated platform. The objective is an integrated healthcare-services platform in the PRC, anchored on specialty hospital services and complemented by hospital management and digital-healthcare cooperation.
Follow regional demand. Management observes that demand for high-quality specialty services is concentrating in regions with more favourable policy environments and mature healthcare ecosystems. The cited service areas are cardiovascular health, sports medicine, preventive care and healthy ageing. This is the rationale for Hainan.
Buy licensed assets. The group will pursue hospital-related acquisitions, specifically interests in hospitals that already hold licences and have an established patient base. The Xiamen deal is the first instance.
Recurring fee base. Hospital management and digital health are positioned as providing a recurring, more balanced revenue base.
Execution philosophy. An action plan built on technology-driven efficiency, optimised resource deployment and innovation, carried out with "prudent optimism".
Initiatives in the last 24 months
| Initiative | Date | Description | Status | Source |
|---|---|---|---|---|
| Yueerwan internet hospital management | Oct 2024 | Five-year management contract with acquisition option | Generating all revenue | AR25-RA |
| Beijing hospital relocation/resumption | FY2025 to FY2026 | Site identified, then reassessed; considering a representative office or health centre | Under review | AR25-RA; AR26 |
| Rights issue | Mar–Jun 2025 | HK$26.79m net; HK$10.6m to shareholder loans, HK$8.3m to hospital business, HK$7.8m to working capital | Fully utilised | AR26 |
| 2025 Share Option Scheme | May 2025 | Scheme mandate of 56,364,998 shares; no grants to date | Adopted | AR26 |
| Hainan Grade III specialty hospital | Dec 2025 | Establishment and site approvals; premises leased | Licence application not yet filed | AR26 |
| Hainan healthcare technology exhibition hall | H1 2026 | AI, wearables, telemedicine showcase and test bed | Operating | AR26 |
| April 2026 share subscription | Apr 2026 | HK$19.09m net, mainly for healthcare investment; HK$6m for working capital to Jan 2027 | Completed | PUBT |
| Capital reorganisation | Apr–Sep 2026 | 5-into-1 consolidation; par cut to HK$0.01; creates approx. HK$55.56m distributable reserve | Effective 22 Sep 2026 | AR26; HKEX-MKT |
| Xiamen hospital acquisition | Jun 2026 | 80% of Chengkan partnership (holds 51% of Xiamen Huli Jianmin Hospital) for RMB5.74m | Pending | PUBT |
Guidance and targets
No quantitative revenue, margin or profitability guidance has been issued. No medium-term financial targets, ESG targets or cost-reduction targets are disclosed.
Products & Services
Hospital management and operational partnership services (current revenue engine)
Yueerwan (Qingdao) Internet Hospital operating partnership. Good Fellow Development provides hospital management services to Yueerwan (Qingdao) Internet Hospital Co., Ltd. and the Qingdao Yueerwan Internet Hospital [AR25-RA].
Fee terms: The higher of:
-
(i) a fixed monthly fee of HK$1.75m; or
-
(ii) 1% of the internet hospital's audited operating revenue plus 10% of its audited profit before tax.
Term: Five years from 25 October 2024. Neither party can terminate without cause in year one. From years two to five, either party may terminate on three months' notice.
Option: Xiamen Yueerwan granted the group an option to acquire all or part of the shares of Yueerwan Qingdao and the Internet Hospital during the term, on terms to be negotiated.
Target customer: The single contractual counterparty.
Launch year: FY2025 (October 2024).
Pricing model: A minimum retainer with a performance kicker.
Economics (derived): The minimum fee implies HK$21.0m per year. FY2026 revenue of HK$20.06m is consistent with the fee being billed at or near the floor, net of any adjustments. The contract therefore accounts for essentially all current revenue.
Termination risk: Because the year-one lock-up expired on 25 October 2025, the counterparty can now exit on three months' notice. This is the single largest risk to the revenue base.
General hospital services (suspended)
Beijing Huicheng Hospital (formerly Beijing Zijing Hospital), Dongcheng District, Beijing.
Services: Medical wards, surgical wards, medical check-up and examination [AR25-RA].
Status: Suspended since 12 December 2024, with no revenue in FY2026 [AR26].
Earlier suspension: A previous suspension ran from 29 December 2023 to around March 2024 after 13 demerit points accumulated in 2023 [HKEX-ANN 3 Jan 2024, 31 Jan 2024; FY24-RA].
Relocation plans: FY2025 management said a new site had been identified in Beijing, with department planning and recruitment under way [AR25-RA].
Latest position: By FY2026 management had reframed this. Given business contraction and structural change in the general-hospital market, it is reassessing whether to reopen at all. Options under consideration include a representative office and a customer-reception health centre [AR26].
Pricing: Not publicly disclosed.
Hainan Grade III specialty hospital (pre-operational)
Approvals: Hainan Good Years Medical Services received a medical institution establishment approval dated 10 December 2025 and a site approval from the Medical Products Administration of the Boao Lecheng International Medical Tourism Pilot Zone [AR26].
Specialty: The interim report summary describes the hospital as a cardiovascular specialty hospital [etnet summary of the 2025/26 Interim Report]. The FY2026 annual report emphasises demand for cardiovascular health, sports medicine, preventive care and healthy ageing [AR26].
Premises: Lease agreements were signed for hospital premises and medical facility space in the Pilot Zone during H1 FY2026, and a dedicated hospital chief executive was appointed [IR26 via Bulletin Express].
Status at report date: Renovation, equipment procurement, hospital IT systems and medical staff recruitment were not complete. The Medical Institution Practising Licence application had not been filed [AR26].
Delays: The employee leading the licence application left the group, and the regulatory approval process and competent authority have changed [AR26].
Timetable: No definitive timetable [AR26].
Bed count, capex budget, pricing: Not publicly disclosed.
Healthcare technology exhibition hall (Boao Lecheng)
During H1 2026 the group established and operated a healthcare technology exhibition hall in the Pilot Zone. It showcases AI, wearable devices, remote consultation and internet-hospital operations [AR26].
Management frames the hall as a market-validation test bed. It says the assets (internet hospital platform, remote consultation facilities, medical AI applications, technical team) can be reused across future projects. The group also exhibited at the 6th China International Consumer Products Expo (Lecheng session) [AR26]. Revenue contribution is not disclosed and is believed to be nil or immaterial.
Historic and discontinued offerings (for completeness)
| Offering | Description | Status | Source |
|---|---|---|---|
| Edinburgh International Hospital, Putian (Fujian) | 200-bed general hospital focused on paediatrics and diabetes, JV with University of Edinburgh | Licensed Jul 2020; Putian hospital no longer reported by FY2024 (group operated one Beijing hospital only). Exit route not confirmed in materials reviewed. | Univ. of Edinburgh; HKEX-ANN 2020; AR25-RA |
| Jiaxing plastic-surgery hospital | Cosmetic surgery hospital | Sold Mar 2020 for HK$11m | AAStocks/uSMART |
| Chongqing hospital consultancy | Consultancy agreement with a Chongqing hospital (2 Jan–1 Mar 2024) to offset the Zijing suspension | Completed | HKEX-ANN 31 Jan 2024 |
| Cosmetic surgery and dermatology | Historic service lines cited by vendors | Not current | AGG (Morningstar) |
Financial Narrative
Income statement
Sources.
-
FY2024–FY2025: AR25-RA (audited).
-
FY2026: AR26 and FY26-RA. FY2026 cost of sales is derived as revenue less gross profit.
-
FY2022–FY2023 revenue: TipRanks/stoxray [AGG]. The FY2023 loss is corroborated by the FY2024 profit warning, which cites HK$5.88m [FY24-RA].
-
FY2022 loss: stoxray [AGG], consistent with the HK$10.6m decline in owners' equity between 1 April 2021 and 1 April 2022 [HKEX-ANN interim FY2023].
Sources: AR25-RA and FY26-RA. No dividends have been declared for FY2024–FY2026. These figures are pre-September 2026 consolidation. Adjusted for the 5-into-1 consolidation, FY2026 loss per share would be approximately -6.2 cents (derived).
All derived. FY2022 growth is calculated against FY2021 revenue of HK$53.886m [AGG]. The revenue CAGR from FY2022 to FY2026 is -22.0% per year (derived).
Reconciliation and disclosure issues.
-
The FY2026 MD&A states revenue growth of "approximately 22.44%", while the Chairman's Statement says 24.44%. Arithmetic (20.060/16.120) supports 24.44% [AR26].
-
The MD&A describes FY2026 gross profit of HK$10.602m as a "decrease of 26.68%". It was in fact an increase of 26.7% from HK$8.369m [AR26].
-
The FY2026 operating loss does not reconcile with the itemised lines disclosed in MD&A. Gross profit 10.602, plus other revenue 0.010, plus other gains 0.626, less S&D 2.290, less admin 14.681, gives -5.733, against the reported -12.373. That leaves approximately HK$6.64m of other charges (derived) not itemised in the sections reviewed. Likely candidates are impairment or expected credit loss items. Investors should check the full income statement on AR26 p.72.
Interim profile (H1 FY2026, six months to 30 Sep 2025) [IR26].
-
Revenue HK$10.500m (H1 FY2025: HK$10.435m).
-
Gross margin 79.37% (78.40%).
-
Loss attributable HK$2.671m, against a profit of HK$7.602m that had been flattered by the HK$10.458m disposal gain.
By subtraction, H2 FY2026 revenue was approximately HK$9.56m. Gross profit was only about HK$2.27m, a gross margin of roughly 24% (derived). This points to a sharp second-half cost step-up, possibly Hainan preparatory staff and exhibition-hall costs charged to cost of sales. It warrants scrutiny.
Commentary on income statement trends
The five-year arc falls into three phases.
FY2021–FY2023: stable decline. Revenue was broadly flat at HK$54–55m, generated by the hospital portfolio after disposals. Losses narrowed from HK$12.7m to HK$5.9m. The improvement was helped in FY2022 by a HK$31.7m one-off disposal gain within the nine-month period [HKEX-ANN 2 Feb 2023].
FY2024: regulatory shock. Revenue fell 29.6% to HK$38.96m. The Beijing hospital was suspended for roughly two months after accumulating 13 regulatory demerit points. The group also took HK$3.5m of non-financial asset impairment and a HK$2.1m loss on PPE disposal [AR25-RA comparatives; FY24-RA]. The attributable loss widened 191% to HK$17.1m.
FY2025–FY2026: collapse of the hospital model and pivot to management fees.
-
The Beijing hospital was suspended again from 12 December 2024 and remained closed through FY2026.
-
Revenue bottomed at HK$16.1m in FY2025, then recovered to HK$20.1m on a full year of Yueerwan fees.
-
FY2025's reported loss was flattered by a HK$10.5m disposal gain. It was simultaneously burdened by a HK$7.8m loss on disposing of hospital PPE.
-
In FY2026 there were no one-offs. The underlying cost base of about HK$17m in S&D plus admin, plus unexplained charges, exceeded gross profit, and the attributable loss widened to HK$12.5m.
Staff costs fell from HK$22.7m (FY2024) to HK$13.1m (FY2025) and HK$9.0m (FY2026) [AR25-RA; AR26]. Headcount fell from 137 to 21, then rose to 28.
Balance sheet
Sources. FY2024–FY2025 from AR25-RA (statement of financial position). FY2026 cash, current assets and current liabilities from AR26 MD&A. Totals, net debt and working capital are derived.
FY2026 gaps.
-
The FY2026 gearing ratio of 5.75% (debt from a director and other loans, divided by total equity) confirms that the group returned to positive equity with minimal debt [AR26].
-
Goodwill and intangibles are shown as zero because no such line appears on the FY2024–FY2025 balance sheets.
Capital-structure disclosure error. AR26 states that issued share capital at 31 March 2026 was HK$57.350m. It then describes this as 563,649,988 ordinary shares, which is the pre-rights-issue count. The correct count is 1,127,299,976 shares at HK$0.05, equal to HK$56.365m, plus 19.7m preference shares at HK$0.05, equal to HK$0.985m, totalling HK$57.350m (derived).
Cash flow
Dividends paid and buybacks were nil throughout FY2024–FY2026 [AR25-RA; AR26].
The main financing inflows in FY2026 were:
-
rights issue net proceeds of HK$26.794m (June 2025), of which HK$10.6m repaid shareholder loans [AR26]; and
-
after the year end, subscription proceeds of HK$19.09m (April 2026).
Ratios
Notes.
-
Current ratios and gearing are as reported [AR25-RA; AR26]. The FY2024 gearing ratio was reported as "N/A" and is entered as 0 to keep the column numeric.
-
Other ratios are derived.
-
ROE, ROIC, net debt/EBITDA and interest coverage are not meaningful. Equity was negative or near zero, EBITDA was negative, and the group was loss-making at operating level in every year shown.
-
The cash conversion cycle cannot be computed (no inventory or trade payables in FY2025–FY2026).
-
Interim note: current ratio at 30 September 2025 was 9.26x, with current liabilities of only HK$1.868m [IR26]. Current liabilities then rose to HK$17.549m by March 2026. The composition of that increase is not disclosed in the excerpts reviewed and warrants checking against AR26 Notes.
Going concern and liquidity
At 31 March 2025 the group had net liabilities of HK$6.755m. The directors relied on the June 2025 rights issue to support the going-concern basis [AR25-RA, Note 2].
By 31 March 2026 the board stated that:
-
the rights issue, shareholder loan repayment, and disposal of non-core loss-making operations had restored the group to net assets; and
-
the April 2026 subscription further strengthened liquidity [AR26].
The capital reduction is intended to create a distributable reserve of approximately HK$55.56m. This is a technical step enabling future distributions or corporate actions, not new capital [AR26].
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Revenue by Segment
| Segment / Stream (HKD Mn) | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
General hospital services (point-in-time) | 38.962 | 10.945 | 0 |
Hospital management services (over time) | 0 | 5.175 | 20.060 |
Total revenue | 38.962 | 16.120 | 20.060 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansSegment share of revenue (%)
| Segment share of revenue (%) | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
General hospital services | 100.0 | 67.9 | 0.0 |
Hospital management services | 0.0 | 32.1 | 100.0 |
Segment YoY growth (%)
| Segment YoY growth (%) | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
General hospital services | -29.6 | -71.9 | -100.0 |
Hospital management services | 0 | 0 | 287.6 |
Total | -29.6 | -58.6 | 24.4 |
Group Entities
| Entity | Role | Status | Source |
|---|---|---|---|
Good Fellow Healthcare Holdings Limited | Listed holding company (Cayman) | Active | AR26 |
Solar Star Global Limited | Immediate holding company (not a subsidiary) | Owned by the Ng family | AR25-RA |
Beijing Huicheng Hospital Co., Ltd. (formerly Beijing Zijing Hospital Co., Limited) | Indirect non-wholly-owned subsidiary; general hospital in Dongcheng District, Beijing | Suspended since 12 Dec 2024 | AR25-RA; HKEX-ANN 3 Jan 2024 |
Good Fellow Development Limited | Indirect wholly-owned subsidiary; counterparty to the Yueerwan management agreement | Active | AR25-RA |
Hainan Good Years Medical Services Co., Ltd. | Indirect wholly-owned subsidiary; Hainan hospital project | Pre-operational | AR26 |
Good Fellow Innovation Co., Ltd. | Indirect wholly-owned subsidiary; tenant of HK office lease (Mar 2024) | Active (per 2024 disclosure) | Zhitong via moomoo |
Sino Business Investment Development Limited | Former direct wholly-owned subsidiary | Disposed 23 Sep 2024 | AR25-RA |
Income Statement
| Metric (HKD Mn) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue | 54.238 | 55.353 | 38.962 | 16.120 | 20.060 |
Cost of sales | — | — | 20.288 | 7.751 | 9.458 |
Gross profit | — | — | 18.674 | 8.369 | 10.602 |
Selling and distribution expenses | — | — | 8.918 | 3.105 | 2.290 |
Administrative expenses | — | — | 20.271 | 15.060 | 14.681 |
Operating loss (reported as loss from operations) | — | — | -16.036 | -7.178 | -12.373 |
Finance costs | — | — | 0.308 | 0.190 | 0.152 |
Loss before tax | — | — | -16.344 | -7.368 | -12.525 |
Loss for the year (total) | — | — | -17.387 | -7.357 | — |
Loss attributable to owners | -12.689 | -5.881 | -17.110 | -10.127 | -12.523 |
Per-share metric (HK cents)
| Per-share metric (HK cents) | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Basic and diluted loss per share | -3.04 | -1.80 | -1.24 |
Dividend per share | 0 | 0 | 0 |
Margin / growth metric (%)
| Margin / growth metric (%) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue growth YoY | 0.7 | 2.1 | -29.6 | -58.6 | 24.4 |
Gross margin | — | — | 47.9 | 51.9 | 52.9 |
Operating margin | — | — | -41.2 | -44.5 | -61.7 |
Net margin (attributable) | -23.4 | -10.6 | -43.9 | -62.8 | -62.4 |
Balance Sheet
| Metric (HKD Mn, at 31 March) | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Property, plant and equipment | 16.035 | 1.273 | — |
Right-of-use assets | 4.138 | 0 | — |
Total non-current assets | 20.441 | 1.273 | — |
Inventories | 1.063 | 0 | — |
Trade and other receivables | 3.761 | 4.414 | — |
Cash and bank balances | 3.644 | 3.829 | 13.391 |
Total current assets | 8.705 | 8.559 | 24.209 |
Total assets | 29.146 | 9.832 | — |
Borrowings (current) | 7.099 | 10.529 | — |
Lease liabilities (current + non-current) | 5.130 | 0 | — |
Total current liabilities | 25.615 | 16.587 | 17.549 |
Total liabilities | 27.739 | 16.587 | — |
Net debt (borrowings + leases − cash) | 8.585 | 6.700 | — |
Working capital (net current assets) | -16.910 | -8.028 | 6.660 |
Equity attributable to owners | 4.357 | -6.509 | — |
Non-controlling interests | -2.950 | -0.246 | — |
Total equity | 1.407 | -6.755 | — |
Goodwill and intangibles | 0 | 0 | — |
Cash Flow
| Metric (HKD Mn) | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|
Operating cash flow | 1.248 | -22.925 | -1.320 | -0.854 |
Financial Ratios (x) and Margin Analysis (%)
| Ratio | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Current ratio (x) | 0.34 | 0.52 | 1.38 |
Gearing ratio as reported (%) | 0 | 99.19 | 5.75 |
ROA (loss for year / average total assets, %) | — | -37.7 | — |
Asset turnover (revenue / average total assets, x) | — | 0.83 | — |
Revenue per employee (HKD Mn) | 0.28 | 0.77 | 0.72 |
Staff costs / revenue (%) | 58.2 | 81.1 | 45.0 |
Region revenue (HKD Mn)
| Region revenue (HKD Mn) | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Mainland China (PRC) | 38.962 | 16.120 | 20.060 |
Hong Kong | 0 | 0 | 0 |
Rest of world | 0 | 0 | 0 |
Region growth YoY (%)
| Region growth YoY (%) | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Mainland China (PRC) | -29.6 | -58.6 | 24.4 |
Share price (HK$, pre-consolidation)
| Share price (HK$, pre-consolidation) | Apr 2025 | Mar 2025 | Feb 2026 | Apr 2026 | Jun 2026 |
|---|---|---|---|---|---|
Observed price | 0.089 | 0.057 | 0.103 | 0.086 | 0.077 |
Capital Markets
| Item | Status |
|---|---|
Sell-side analyst consensus | None identified |
Dividend history | No dividends for FY2024–FY2026; no distributable reserves at 31 Mar 2026 (AR26) |
Dividend policy | Not formally disclosed; the capital reduction creates an approx. HK$55.56m distributable reserve |
Buyback authorisation | Repurchase mandate of up to 10% of issued shares sought at the 9 Sep 2026 AGM; no repurchases in FY2025 |
Credit ratings (Moody's / S&P / Fitch) | Not rated |
Bank borrowings | None at 31 Mar 2025 or 2026; no asset charges (AR25-RA; AR26) |
Debt maturity profile | Not applicable beyond small director and other loans (gearing 5.75%) |
Share capital metric (millions of shares)
| Share capital metric (millions of shares) | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 |
|---|---|---|---|---|---|
Ordinary shares in issue | 2,818.25 | 563.65 | 563.65 | 1,127.30 | 270.55 |
Analyst Conclusions
Management guidance
There is no numerical guidance. Management's qualitative priorities are:
-
advance the Hainan Grade III hospital, without a timetable;
-
complete the Xiamen hospital acquisition;
-
keep evaluating licensed-hospital acquisitions;
-
sustain the Yueerwan management relationship;
-
decide the configuration of the Beijing business (representative office or health centre) [AR26].
Consensus expectations. None, as there is no coverage.
Bull case
-
Floor revenue plus optionality. The HK$21m-per-year Yueerwan minimum fee covers most of the cash cost base (S&D plus admin of about HK$17m in FY2026). The acquisition option and Xiamen deal could convert the group into an owner of licensed assets cheaply, at RMB5.74m for a look-through 40.8% hospital interest.
-
Clean balance sheet for a pivot. Cash of HK$13.4m at March 2026 plus HK$19.1m raised in April 2026, together with near-zero debt, gives roughly HK$30m+ of dry powder (derived, before FY2027 burn) for small acquisitions.
-
Hainan scarcity value. Valid Grade III specialty-hospital approvals in Boao Lecheng have value in themselves, and could be monetised or partnered even if the group does not build out alone.
Bear case
-
One contract away from zero revenue. The counterparty may terminate on three months' notice. Loss of the contract would leave the group with no revenue-generating operations.
-
Losses and dilution are structural. The attributable loss widened to HK$12.5m despite 24% revenue growth. There is about HK$6.6m of unexplained charges and an H2 gross margin of about 24%. Shares in issue rose 2.4x in ten months.
-
Execution and governance credibility. The record includes:
-
repeated Beijing suspensions;
-
Hainan licensing slippage;
-
a reorganisation delayed by an incomplete Cayman filing;
-
multiple errors in the annual report;
-
a 26.6% share security interest;
-
an acquisition target with a large net loss and questionable reported net liabilities.
-
Catalysts and monitorables (next 12 months)
-
Completion, final terms and financing of the Xiamen Huli Jianmin acquisition, and restated target financials (net liabilities).
-
Any notice or renegotiation under the Yueerwan agreement, or exercise of the acquisition option.
-
Filing and grant of the Hainan Medical Institution Practising Licence; construction and capex disclosures.
-
Decision on the Beijing Huicheng business (closure, write-off or health-centre format).
-
Interim results for H1 FY2027 (six months to 30 Sep 2026), due around November 2026: cash burn, the H2-style margin compression, and the use of April proceeds.
-
Further equity issuance under the AGM mandate and any changes to the Dejin Liangpin security interest or the controlling stake.
-
Post-consolidation trading liquidity and GEM compliance.
Analyst verdict
Good Fellow Healthcare is best understood today as a listed shell in transition, not an operating hospital group. Its revenue line, HK$20.06m in FY2026, is one management contract with a contractual floor. That contract became cancellable on short notice in October 2025.
The group's only hospital has been dark for nearly two years. The flagship Hainan project has approvals but no licence application, no budget and no timetable. Senior capability is thin: 28 staff, no CEO, and no medical leader on the board.
Against that, the board has done the necessary balance-sheet triage:
-
negative equity was repaired;
-
shareholder loans were repaid;
-
bank debt was eliminated;
-
roughly HK$46m of net equity capital was raised across two transactions;
-
the capital structure was simplified to meet GEM trading norms.
The new strategy of buying already-licensed hospitals cheaply is coherent in a PRC market where private hospital numbers are now shrinking and distressed assets are available. The question is whether this team can operate them better than the previous owners, given its own regulatory track record in Beijing.
Disclosure quality is a material concern. The FY2026 annual report contains arithmetic and narrative errors. Operating charges of about HK$6.6m are not itemised in the sections reviewed. The first acquisition target's reported net liabilities, at around RMB772m, are implausible on their face. A security interest over more than a quarter of the shares adds control uncertainty.
For institutional purposes, the equity is uninvestable on fundamentals. It has no coverage, minimal liquidity, persistent losses and serial dilution. It is relevant only as a special situation contingent on:
-
completion and transparent consolidation of the Xiamen hospital;
-
retention of the Yueerwan contract; and
-
tangible Hainan licensing progress.
Verdict: High risk / Speculative. Monitor for evidence of operating-asset accretion before assigning value beyond net cash.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Title | Appointed | Age | Education / prior roles | Source |
|---|---|---|---|---|---|
Ng Chi Lung | Chairman, Executive Director, Compliance Officer, Chair of Nomination and CG Committee; controlling shareholder | 23 Jul 2018 | 37 | Diploma, Sydney Institute of Business and Technology (2008); studied accounting at Macquarie University. Founder of manufacturing and services businesses since 2012. ED of Yueshou Environmental (now China Gem Holdings, 1191.HK) 2014–2016; Vice Chairman and ED of Theme International (990.HK) 2016–2018 | AR26 |
Wu Qiyou | Executive Director; Remuneration Committee member | 22 Aug 2023 | 32 | B.Bus (Banking and Finance, 2016) and MBA (2022), Monash University. Investment manager, Cornerstone Capital Investment Group (2016–2020); management team, Lunghealth Medtech (2021–2022, magnetic navigation bronchoscopy); founder and CEO, Dynamiq Advisory Pte Ltd (since Dec 2022) | AR26 |
Wong Ka Wai, Jeanne | INED; Chair of Audit and Remuneration Committees | 1 Nov 2007 | 62 | B.Econ, University of Sydney; CA ANZ, HKICPA, STEP, Certified Tax Adviser. MD of a consulting firm, CFO of a local law firm. INED of Phoenitron Holdings (8066.HK) | AR26 |
Lau Tak Kei Arthur | INED | 4 Oct 2019 | 44 | LLB (LSE); M.Econ (HKU); SFC Type 4/9 licensed. Co-founder and partner of Ark Pacific Capital Management. Former investment director, Elliott Advisors (HK); Citigroup TMT investment banking; started at JPMorgan. Member of the Beijing Municipal Committee of the CPPCC | AR26 |
Lin Yaomin | INED | 17 Apr 2024 | 65 | B.Sc Nanjing University (1982); M.Sc Chinese Academy of Sciences; senior economist; FLMI (1999). GM of Ping An Life Xiamen (1995–2000) and Hubei (2000–2002); Kunlun Health Insurance (2006–2015), latterly Chairman and CEO; senior consultant, Airstar Digital Technology (2017–2021); founder of Insurance Today research institute | AR26 |
Lam Williamson | CFO and Company Secretary; Authorised Representative | Joined Dec 2007 | 51 | CPA Australia; FCPA (HKICPA) | AR26 |
Directors' Remuneration
| Attribute | Detail |
|---|---|
Board size | 5 (2 executive, 3 INEDs) |
Independence | 60% INEDs |
Chair/CEO separation | No CEO; Chairman is the controlling shareholder |
Gender | 1 female of 5 directors (20%) |
Board meetings FY2026 | 10 (100% attendance; Lin Yaomin 9/9) |
Audit Committee | Wong (Chair), Lau, Lin; 2 meetings in FY2026 |
Remuneration Committee | Wong (Chair), Wu, Lau, Lin; 2 meetings |
Nomination and CG Committee | Ng (Chair), Wong, Lau, Lin; 2 meetings |
Retiring at 2026 AGM (9 Sep 2026) | Wu Qiyou, Lau Tak Kei Arthur (eligible for re-election) |
Board & Management Changes
| Date | Change | Source |
|---|---|---|
22 Aug 2023 | Board reshuffle; Wu Qiyou appointed ED | AR26; Zonebourse |
17 Apr 2024 | Lin Yaomin appointed INED | AR25-RA |
H1 FY2026 | Dedicated hospital chief executive appointed for the Hainan project (name not disclosed) | IR26 |
H1 2026 | Employee leading the Hainan licence application departed | AR26 |
Shareholding Trend
| Holder | Shares at 31 Mar 2026 | % at 31 Mar 2026 | % after 28 Apr 2026 subscription | Source |
|---|---|---|---|---|
Solar Star Global Ltd (Ng family vehicle) | 632,783,784 | 56.13 | 46.78 (derived) | AR26 |
Ng Chi Lung (personal) | 23,600,000 | 2.09 | 1.74 (derived) | AR26 |
Ng Chi Lung and family (aggregate, incl. spouse Cheng Wai Yin) | 656,383,784 | 58.22 | 48.52 | AR26; PUBT 28 Apr 2026 |
New Hope International (HK) Ltd (ultimately Liu Yonghao) | 68,643,507 | 6.09 | 5.07 (derived) | AR26 |
| — | 0 | 0 | 8.33 | PUBT 28 Apr 2026 |
| — | 0 | 0 | 8.33 | PUBT 28 Apr 2026 |
Dejin Liangpin Co., Ltd (Wang Shaofeng) | 300,000,000 (security interest) | 26.61 | 22.18 (derived) | AR26 |
Competitive Landscape
Key Competitors
| Competitor (ticker) | Segment overlap | Relative positioning vs. Good Fellow |
|---|---|---|
Genertec Universal Medical (2666.HK) | Hospital groups | State-backed scale operator; Good Fellow is orders of magnitude smaller |
China Resources Medical (1515.HK) | Hospital groups | SOE-backed hospital network; illustrates the PRC trend of closing loss-making private hospitals (it applied to close Huaiyin Hospital in 2024) |
Hygeia Healthcare (6078.HK) | Specialty hospitals | Specialty oncology chain; the type of licensed-network model Good Fellow aspires to |
New Century Healthcare (1518.HK) | Specialty (paediatric) hospitals, Beijing | Direct Beijing private-hospital comparator |
Jinxin Fertility (1951.HK) | Specialty/consumer healthcare | Consumer-pay specialty model |
Xikang Cloud Hospital (9686.HK) | Internet hospital / cloud hospital | H1 2026 revenue RMB182.9m, gross margin 23.5% (Xikang interim announcement, 26 Aug 2026), roughly 18x Good Fellow's half-year revenue |
Ping An Healthcare and Technology (1833.HK) | Internet hospital / telemedicine | Platform scale, insurance-linked |
JD Health (6618.HK) | Internet hospital / online pharmacy | Platform scale |
Alibaba Health (0241.HK) | Internet hospital / online pharmacy | Platform scale |
Boao Lecheng operators (36 operational institutions as of July 2025) | Hainan medical tourism | Established incumbents in the zone Good Fellow plans to enter |
Peer Comparison FY2026
| Metric | Good Fellow (FY2026) | Xikang Cloud Hospital (H1 2026) |
|---|---|---|
Revenue | HK$20.06m (full year) | RMB182.9m (half year) |
Gross margin | 52.9% | 23.5% |
Net result | Attributable loss HK$12.52m | Loss RMB27.4m (half year) |
Recent Developments
--



